Home / Market News / $AMGN
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Hold on Amgen, Raises Price Target to $380

Oct 7, 2026, 3:05 PM UTC · Primary ticker $AMGN

Truist Securities analyst Gregory Renza has reiterated a 'Hold' rating on Amgen (AMGN) while increasing its price target from $362 to $380. This indicates a slightly more optimistic outlook on the stock's valuation by the analyst, though not enough to warrant an upgrade to a 'Buy' rating.

Truist Securities analyst Gregory Renza has maintained a 'Hold' rating on Amgen (AMGN) but raised the price target from $362 to $380. This action suggests that while the analyst sees some upside potential for Amgen, they do not believe it's a strong 'Buy' at current levels. This is a moderate catalyst for traders, as a price target increase, even with a maintained 'Hold' rating, can sometimes provide a small positive sentiment boost. The primary impact is on Amgen, as it reflects an updated valuation perspective from a notable financial institution. Short-term, this could lead to minor positive price movement, but long-term implications are limited without a change in the actual rating. The key opportunity for traders is to observe if other analysts follow suit or if this signals a broader shift in sentiment towards Amgen's valuation.

$AMGN neutral Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.